Poseida Therapeutics (PSTX) Earnings Date & Reports
Get AI intraday signals
A.I. Advisor
published Earnings
PSTX is expected to report earnings to fall 257.14% to -33 cents per share on March 06
Q4'24
Est.
$-0.33
Q3'24
Beat
by $0.63
Q2'24
Beat
by $0.09
Q1'24
Beat
by $0.17
Q4'23
Beat
by $0.12
The last earnings report on November 07 showed earnings per share of 20 cents, beating the estimate of -41 cents. With 597.85K shares outstanding, the current market capitalization sits at 925.93M.
a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors